Keros Therapeutics, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized
Keros Therapeutics, Inc. (KROS) reported Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized of 3.08 million shares for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-03.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized · last filed 2026-08-03
- Keros Therapeutics, Inc. share-based compensation arrangement by share-based payment award, number of additional shares authorized for the quarter ending 2026-06-30 was -24.09K shares, a 147.23% decline year-over-year.
- Keros Therapeutics, Inc. share-based compensation arrangement by share-based payment award, number of additional shares authorized for the quarter ending 2026-03-31 was 3.11M shares, a 89.56% increase year-over-year.
- Keros Therapeutics, Inc. share-based compensation arrangement by share-based payment award, number of additional shares authorized for the quarter ending 2025-09-30 was 864.63K shares.
- Keros Therapeutics, Inc. share-based compensation arrangement by share-based payment award, number of additional shares authorized for the quarter ending 2025-06-30 was 51.02K shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized 1 month | Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized 9 month |
|---|---|---|---|---|
| 2026-06-30 | -24.09K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-03 | 3.08M shares 10-Q · filed 2026-08-03 | ||
| 2026-03-31 | 3.11M shares 10-Q · filed 2026-05-14 | |||
| 2025-09-30 | 864.63K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | 915.64K shares derived: sum of 2 quarters · filed 2025-11-05 | 2.55M shares 10-Q · filed 2025-11-05 | |
| 2025-06-30 | 51.02K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | 1.69M shares 10-Q · filed 2025-08-06 | ||
| 2025-03-31 | 1.64M shares 10-Q · filed 2025-05-06 | |||
| 2020-03-31 | 2.10M shares 10-Q · filed 2020-08-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| NATURES SUNSHINE PRODUCTS INC (NATR) | United States | $0.228B | 20.51 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| Whitehawk Therapeutics, Inc. (WHWK) | United States | $0.221B | |
| Eledon Pharmaceuticals, Inc. (ELDN) | United States | $0.219B | -3.23 |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |